Tuesday, October 9, 2012
Isconova AB, of Uppsala, Sweden, said its partner, the Jenner Institute at Oxford University, received approval from the UK's Medicines and Healthcare products Regulatory Agency to start a Phase I study of a malaria vaccine candidate containing Isconova's adjuvant Matrix-M.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.